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ABSTRACT
Background: Offering living kidney donation raised the
concern that donors are exposed to unknown risks. All
Swiss transplant centres therefore decided to start
a prospective cohort study of living kidney donors in
Switzerland. This paper describes the rationale for and
implementation of this cohort study.
Methods/design: All kidney donors in Switzerland are
registered and examined before donation and
biennially after donation starting in the ﬁrst year after
nephrectomy. Before each follow-up visit, the study
centre sends a package to the kidney donor containing
the health questionnaire, blood and urine tubes and
a prepaid envelope for sending the samples to the
central laboratory. The donor makes an appointment
with their family physician, who examines the donor
and reports ﬁndings such as pain and other
complaints, blood pressure, creatinine, albumin, all
major health events and the state of mental and social
well-being to the study centre. The family doctor draws
the blood sample and mails it with the urine sample in
the prepaid envelope. All data are centrally managed.
All abnormal ﬁndings in the follow-up of individual
donors are regularly discussed with the principal
investigator, and necessary clinical changes made and
recorded in the database. The health insurance of the
recipient covers all costs of the donor follow-up. The
main outcomes are the occurrence of albuminuria,
hypertension and renal insufﬁciency. The secondary
outcomes are major somatic and social events such as
death, cardiovascular disease, stroke and depression.
Discussion: This prospective cohort offers unique
opportunities to assess the risks of living kidney
donation and will allow us to examine the risks
associated with the methods used for nephrectomy in
Switzerland (various forms of open surgery and
laparoscopic nephrectomy). The prospective collection
of all clinically relevant data and the regular monitoring
of donors will allow timely interventions at early stages
before serious kidney and general health problems
occur.
BACKGROUND
Living kidney donors have been used in
Switzerland since 1967 but at a low rate. This,
however, changed in the early 1990s. Rapid
expansion of live kidney transplantation took
place mainly in two large Swiss transplant
centres Basel and Zu ¨rich. The latter had
strictly disapproved all living organ donations
for the two previous decades on ethical
grounds. The increase in live donor trans-
plantation was not universally regarded as
a beneﬁt. A lawyer wrote in the Swiss Medical
Journal that ‘organ removal from a living
person for transplantation is an intended
bodily injury according to civil and criminal
law’.
1 Concerns were raised over the safety of
live organ donation for the donors. The
available published data from retrospective
studies were largely incomplete. In these
studies, the percentage of donors without
follow-up data ranged from 21%
23to 31%,
4
to 42%
56up to 77%.
7 Indeed, given the
available evidence, fair counselling of poten-
tial living donors is challenging.
Since living-donor transplantation was
mainly propagated by the Basel transplant
centre, we felt obliged to offer a long-term
follow-up of the health state of living organ
donors for all Swiss transplant centres. This
idea was well accepted by the other ﬁve
Swiss centres (Bern, Geneva, Lausanne, St
Gallen and Zu ¨rich), and consequently, the
cohort study by the name of the Swiss Organ
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ARTICLE SUMMARY
Article focus
- To describe the rationale and set-up of the Swiss
Living Kidney Donor Cohort Study.
Key messages
- The question of whether kidney donation
increases health risks such as hypertension and
renal failure is still unsettled.
- Data for this countrywide prospective cohort
study over the period of at least 18 years will
answer many still open questions concerning
living kidney donor outcome.
Strengths and limitations of this study
- This countrywide cohort study includes all
consenting Swiss living kidney donors.
- This is a long-term follow-up allowing the
assessment of clinically relevant outcomes of
donation such as hypertension and renal failure.
- We cannot completely rule out residual
confounding in this observational study.
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Open Access ProtocolLiving Donor Health Registry (SOL-DHR) was initiated
in April 1993.
This paper describes the rationale for, and imple-
mentation of, this prospective cohort study. We aim to
assess the prevalence of complications of living kidney
donation and to identify risk proﬁles associated with
unfavourable outcomes. We will assess the results of
different surgical options for donation. In particular, the
study is designed to prospectively quantify the risks to
donors after living kidney donation: the development of
hypertension, albuminuria, renal failure and psycholog-
ical diseases. The infrastructure will also assist in the
management of individual donors at an early stage if
such complications occur.
METHODS
Prospective cohort study
There was a priori consensus among the founding
members that a lifelong assessment of the health state of
all consenting eligible living kidney donors should be
made at regular time intervals in the context of
a prospective cohort study. The protocol and question-
naires were approved by the Ethical Committee of the
University Hospital of Basel and the Swiss Academy of
Medical Science (SAMW). No informed consent is
required, as a lifelong follow-up of the living donor’s
health state is required by the Swiss Transplant Law
and may be studied as long as data are analysed anony-
mously. However, to ensure compliance with the long-
term follow-up protocol, donors are informed about the
aims of the protocol and the registry before their
donation. In addition, kidney donors have at any time
after donation the option to stop participating by simply
ignoring the invitation from SOL-DHR to visit their
family physician.
Donors from all six kidney transplant centres have
been included in the SOL-DHR since 1993. Until the
end of 2010, a total of 1332 living kidney donors have
been included (Basel, n¼521; Berne, n¼119; Geneva,
n¼111; Lausanne, n¼151; St Gallen, n¼79; Zurich,
n¼360).
Main objectives
The main objectives were as follows:
< obtain prospective outcome data from consecutive
living kidney donors in Switzerland;
< quantify the risks for early and late complications
owing to nephrectomy;
< improve the information given to future potential
donors before agreeing to donate a kidney and
to produce standardised evidence-based educational
materials;
< install a system of timely intervention in case of
development of markers of increased risk or new
health problems;
< compare outcomes from different methods of
nephrectomy;
< provide a neutral platform for donors to express
complaints and receive help.
Data-collection principles
Before kidney donation, the transplant centre is
responsible for including patients in the study and for
the ﬁrst medical examination before kidney donation
(see basic medical questionnaire below). At the time of
discharge after nephrectomy, the transplant centre
submits a second questionnaire (the early-complications
questionnaire). Thereafter, the SOL-DHR centre orga-
nises a lifelong follow-up after nephrectomy at 1 year,
3 years, 5 years, 7 years, 10 years and biennially there-
after. The kidney donors are examined by their family
physicians in the vicinity where they live. Before each
follow-up visit, the SOL-DHR centre sends a package to
the kidney donor asking the donor to make an
appointment with the present family physician of their
choice. This contains the brief information for the
donor and the family physician, a health questionnaire,
tubes for blood and urine samples, and a prepaid
envelope for sending the samples at room temperature
to the central laboratory (Viollier AG Basel,
Switzerland). The basic biennial follow-up questionnaire
is ﬁlled in by the family physician. Every 5 years, the
donor ﬁlls in the additional Eight-Item Short-Form
(SF-8) and social-status questionnaire (see below).
If no response from the donor is received within
2 months after the follow-up material was sent out,
SOL-DHR initiates a search for the donor, contacting the
recipient, the donor’s health insurance and the public
registries to identify whether the donor has died and, if
so, the cause of death.
Results from the blood and urine analysis by the
central laboratory are sent to the family physician and to
the cohort manager at SOL-DHR.
Participation of family physicians
Whereas kidney recipients usually live in the area of the
transplant centre, kidney donors often do not. Donors
are not likely to adhere to a recommendation to travel
lifelong biennially to a distant transplant centre for
follow-up, particularly since travel expenses are not
covered. We believe that adherence will be much greater
if a follow-up can be coordinated by the patient’s own
local family physician. Family physicians, aided by
trainees at the transplant centre, follow the protocols
provided by the study centre.
Collected data
Laboratory data
We analyse creatinine in blood and urine, albumin and
protein in urine centrally. The method used to quantify
creatinine in blood changed over the years: 1993e1996
Jaffee, 1997e2003 enzymatic assay (Roche AG Basel,
Switzerland), 2004e2005 ‘Jaffe compensated’ (Roche),
2006eAugust 2007 ‘Jaffe corrected’ (Siemens, Schweiz
AG, Zu ¨rich, Switzerland), and since September 2007 an
enzymatic assay (Siemens). In order to avoid systematic
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entry all values are converted to values traceable to
isotope dilution mass spectrometry (IDMS) as recom-
mended by the Kidney Disease: Improving Global
Outcomes consensus conference
8 using calibration data
supplied by the assay’s manufacturers (data available on
request). Albumin in urine is measured by turbidimetry
after antigeneantibody reaction using the endpoint
method (Roche).Whenever during a follow-up a labora-
tory result (creatinine or albumin/creatinine ratio)
exceeds the expected range in an individual donor, the
sampling and the laboratory analysis are repeated.
Deﬁnitions
Estimation of glomerular ﬁltration rate (GFR)
To estimate GFR, we use the MDRD equation for IDMS-
traceable creatinine values:
9
eGFRðmL=min=1:73 m
2
¼ 1753ðScr=88:4Þ
 1:1543
ðAgeÞ
 0:2033ð0:742
 Þ3ð1:212
þÞ If femaleþIf African
Microalbuminuria (¼high albumin excretion)
We assume a daily urinary excretion of 10 mmol creati-
nine/day as being normal for donors (using this mean
value for both genders taken together; an underestimate
for males, and an overestimate for females). We will
report albuminuria as albumin:creatinine ratios using
the cut-off point deﬁned by the report of the scientiﬁc
workshop sponsored by the National Kidney Foundation
and the US Food and Drug Administration.
10 The cut-off
point for microalbuminuria or high albumin excretion is
>30 mg/g ($3.3 mg/mmol). For clarity, we will use the
term microalbuminuria, which is commonly used in
Europe, rather than the term ‘high albumin excretion’
used in North America. The cut-off point for macro-
albuminuria (proteinuria) or very high albumin excre-
tion is >300 mg/g (>33.9 mg/mmol).
Hypertension
Donors who have a systolic pressure above 140 mm Hg
or diastolic pressure above 90 mm Hg or both or who
are taking any antihypertensive drug are classiﬁed as
hypertensive. In any case of new-onset hypertension, we
ask the family physician to perform a 24 h ambulatory
blood pressure recording. If hypertension is conﬁrmed,
we recommend antihypertensive treatment with and
ACE inhibitor or an angiotensin-receptor blocker.
HEALTH-STATUS DATA
At each visit, the family physician is asked to measure the
actual weight, height and blood pressure (three times in
the sitting position), and the bare abdomen of the donor
in an upright posture to look for an incisional hernia or
abdominal wall bulging caused by the nephrectomy.
When the donor is complaining about pain in any
speciﬁc place (eg, lumbar back pain), it should be
examined and evaluated whether it is or could be caus-
ally related to nephrectomy. We ask for careful docu-
mentation of new symptoms, comorbidities or other
problems (somatic, mental or social).
Questionnaires
Basic medical questionnaire to be collected before donation
The basic medical questionnaire collects information on
body weight, sitting blood pressure (three times),
description of the nephrectomy scare, pain or new
problems since the last examination and an inventory of
all drugs currently taken. The questionnaire before
donation also includes ‘major disease and back pain,’
since we realise that back pain is such a common
complaint that we need information before donation in
order classify back pain after donation in a meaningful
way.
Early-complication questionnaire to be collected at the time
of hospital discharge after nephrectomy (since 1998)
This questionnaire collects data on the side and method
used for nephrectomy and all complications occurring
peri- and postoperatively including blood transfusions,
whether the endoscopic procedure had to be changed
intraoperatively and whether surgical revision was
necessary. Early postoperative pain, which reﬂects pain
at the site of incision and sometimes in case of endo-
scopic nephrectomy additional shoulder pain due to
body positioning during surgery, is assessed using the
visual analogue scale. The questionnaire is ﬁlled out
usually 2 weeks after nephrectomy. For grading early
complications, we use the Clavien scale.
11 Every early
complication observed in a donor is classiﬁed along the
Clavien scale (Grade I¼1, grade II¼2, grade IIIa¼3,
grade IIIb¼3.5, grade IVa¼4, grade IVb¼4.5, etc). If
multiple complications occur in the same donor,
the single Clavien scores are added to what is called the
Clavien sum per donor score. We also calculate
the simple sum of observed complications per donor.
The two sums have different interpretations. For a given
group of donors, for example, older than 60 years, the
mean simple sum of complications shows the frequency
of early complications seen in older donors, whereas the
mean Clavien sum shows their severity.
Basic biennial follow-up questionnaire
We ask the family physician to measure body weight and
sitting blood pressure (three times), examine the
nephrectomy scar and take an interim medical history in
order to complete the medical questionnaire. This
includes questions about pain and all serious health
problems (eg, stroke, cardiovascular events, diabetes or
malignancies) since the last examination. Back pain is
considered to be related to the nephrectomy only if
speciﬁed by the donor or their physician as being clearly
more intense than before donation. (Pain related to
nephrectomy can be caused by instability of the
abdominal wall after large lumbar incision with partial
muscular palsy.) The family physician records all drugs
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tion of the urine, ﬁlls the blood and urine phials, and
sends both phials to the central laboratory. If the urinary
dipstick turns out to be positive for blood, protein, white
blood cells or other abnormalities, we request that the
family doctor make an additional microscopic examina-
tion of the urinary sediment. All clinical data are sent to
the SOL-DHR study centre.
The SF-8 questionnaire has been collected every 5 years
after donation since 2002. The validated SF-8 multiple
choice questionnaire is used to calculate the Physical
Component Summary and Mental Component Summary
We ask three supplementary multiple-choice ques-
tions, which are analysed separately: (1) In comparison
with 1 year ago, how would you describe your actual
health? (2) How has your emotional relationship with
the kidney recipient changed since donation? (3) Would
you donate a kidney again, if you still had two kidneys?
Social-status questionnaire
Since 2002, we have used an instrument developed by
SOL-DHR that contains multiple-choice questions about
the actual professional activity, working capacity, efﬁ-
ciency and physical ﬁtness of the donor, along with two
open questions: (1) drawbacks because of donation (eg,
ﬁnancial, insurance, pension fund or professional
disadvantages) and (2) donor’s suggestions for possible
improvement for SOL-DHR activities (What can SOL-
DHR do better for you?).
Data monitoring and quality assurance
All incoming data are checked by staff for completeness
and plausibility, and are entered into an electronic
database. In case of missing or implausible data, we call
the ofﬁce of the family physician and attempt to rectify
this. Once or twice a month, staff discuss any donor with
an abnormality with the principal investigator. Urgent
cases are discussed immediately, and interventions are
initiated without delay. All outcomes are stored within
the database.
The ‘principle of intervention’ is a key feature of this
cohort study. Thus, we not only observe our cohort but
also intervene actively, as soon as any risk factor changes
or clinical problem develops. Study leaders make recom-
mendations for interventions which are then imple-
mented by the family physician. Recommendations may
include performing a diagnostic procedure such as 24 h
ambulatory blood pressure measurement in order to
conﬁrm hypertension, to perform an ultrasound of the
remaining kidney or to repeat the chemical analysis. The
letter may also contain a recommendation for treatment.
Funding of SOL-DHR and reimbursement for follow-up
examinations
The SOL-DHR expenses are funded by the Swiss Foun-
dation for the follow-up care of living organ donors
(SNO). The SNO is supported by the government,
research and industry funds as well as the Swiss Society of
Nephrology. The detailed list of sponsors is given at the
end of the manuscript. The running costs of SOL-DHR
are kept low, as organisation and medical activities of
SOL-DHR have been provided on a volunteer basis by
GTT since 1993 and by DT since 2000.
The basic concept is to cover the costs of kidney donor
follow-up via the insurance company of the kidney
recipient, because they would have paid ongoing dialysis
costs had no living donation taken place. Coverage
includes all costs including those of late complications of
the donor that are causally related to the donation.
Hence, Swiss transplant law requires the health insur-
ance of the kidney recipients to cover the bills from the
family physicians for biennial donor follow-up
(according to a ﬁxed payment schedule) as long as the
recipient is alive. After the recipients’ death, the bills for
the donor follow-up are covered by SNO. The bills for
donor follow-up examination are sent to the SOL-DHR
centre, which forwards the bill to the health insurance of
the kidney recipient. The costs for the chemical analysis
in blood and urine of donors have been covered by
Violliers AG Basel since 1993. The cost for drugs
required by the donor is paid by the compulsory health
insurance of the donor, whether the drug treatment is
related to donation or not.
Handling missing responses
If no response is received by 2 months after an invitation
has been sent (a ﬁlled out questionnaire from the donor,
the family physician or laboratory) SOL-DHR staff call
the donor. If the donor declines to participate further,
they will be marked ‘inactive’ in the cohort database, and
follow-up is suspended. If the donor later changes their
mind, and gets in touch with us again (eg, after moving
back to Switzerland), the status is changed back to
‘active’ immediately.
Control population
To control for the risk of developing hypertension, we
plan to use two different reference groups. First, we will
compare the incidence and prevalence of hypertension
in our cohort with that of the Monitoring of Trends and
Determinants in Cardiovascular Disease Study (data
from a normal Swiss population).
12e14 Second, since
living donors are positively selected from the normal
population, we consider them to be ‘healthier’ than the
normal population, resulting in a potential under-
reporting of health risks. To directly compare the
normal outcome of such a healthy cohort, pooled data
from the SOL-DHR’s own healthy donor population
taken prior to nephrectomy (n¼1332) are used to
analyse the outcome of this positively selected donor
population after donation.
STATISTICAL CONSIDERATIONS
Continuous data will be presented with medians, inter-
quartile ranges or means and standard deviations as
appropriate, and categorical data as rates and
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with the outcome variables will be reported using corre-
lation coefﬁcients. Main outcomes are the occurrence of
albuminuria, hypertension and renal insufﬁciency as
speciﬁed above. Secondary outcomes are major somatic
and social events such as death, cardiovascular disease,
stroke and depression collected from the questionnaires.
All outcomes are considered to be dichotomous.
Results from univariate analysis will inform multivari-
able modelling. Assessment of causal associations will be
performed using multivariable models including poten-
tial confounders along with the independent variables of
interest. Prognostic scores will be built using either
multivariate logistic regression analysis or Cox propor-
tional hazard models. Models will be validated in cross-
samples. Calibration and discrimination of the cross-
validated prognostic instruments will be assessed
using the Brier Score. Time-series analysis will be
performed using random-effects regression models
where appropriate.
Sample-size calculations
The analysis is based on the example of hypertension.
We assume that one additional kidney donor out of 15
(controls) will develop hypertension. We further assume
a follow-up after the accrual interval of 10 years. Prior
data indicate that the median time for onset of hyper-
tension (survival time) on the control treatment is
5 years. If the true median survival times on the experi-
mental and control treatments are 5 and 10 years,
respectively, we will need to study 29 subjects developing
hypertension and 435 control subjects to be able to
reject the null hypothesis that the experimental (post-
surgery) and control (presurgery) survival curves are
equal with probability (power) 80%. The Type I
error probability associated with this test of this null
hypothesis is 0.05.
DISCUSSION
This paper describes the rationale for, and organisation
of, a lifelong prospective cohort study of living kidney
donors in Switzerland. This study offers unique oppor-
tunities to assess the frequency of occurrence of unfav-
ourable outcomes following donation and allows risk
factors associated with them to be determined. More
speciﬁcally, we are particularly interested in increasing
our understanding of the long-term effect of donation
on renal function and the risk of developing hyperten-
sion or albuminuria, and exploring whether adverse
outcomes depend on the method of nephrectomy
applied. Moreover, the systematic collection of all clini-
cally relevant data and the monitoring of participants on
a regular basis allow timely interventions if kidney
functions or general health change for the worse.
Overview of the existing evidence
In the 1980s and early 1990s, many interesting papers
were already available.
2e7 15e23 They all tried to quantify
the morbidity and mortality of living kidney donation or
unilateral nephrectomy. Most data derive from single
centres in the USA, some from Norway or Australia.
Unfortunately, all published data were collected retro-
spectively, resulting in incomplete data sets, and the
data were affected by selection bias. Based on these
retrospective studies, kidney donation is now generally
accepted as a relatively safe procedure, but long-term
data prospective studies of consecutive patients are
lacking.
24e27
Up to now, prospective long-term follow-up of living
donors has not been regarded generally as a necessity. A
prospective long-term follow-up study of living donors as
set out in the present protocol is likely to improve the
quality of the data on the short- and medium-term safety
of living kidney donation, but also allows for timely
intervention if an individual donor experiences a poten-
tial problem. Data generated will inform policy on
optimal long-term donor follow-up.
In addition, new questions such as the effect of various
surgical techniques have arisen recently. Several methods
of endoscopic (including robotically assisted) nephrec-
tomy have been introduced and have been shown to be
relatively safe.
28e38 Single-centre reports mainly concen-
trate on a single technology rather than providing unbi-
ased comparisons of different methods.
30 33e36 To our
knowledge, no national prospective cohorts have yet
reported on these issues, and those that are planned will
compare only two methods.
32
The question of whether kidney donation increases
the risk for hypertension, which had already been
debated in the 1980s,
4 16 22 is still unsettled owing to the
limited number of studies.
29 We think that the results of
this large, nationwide, prospective cohort study will
address many important unanswered questions about
outcomes in living kidney donors.
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